The American Association of Endocrinologists and the American Diabetes Association believe that the study published online Feb. 25 in JAMA Internal Medicine regarding a relationship between GLP-1-based therapy and pancreatitis does not provide the basis for changing treatment in people with diabetes. Despite the reported two-fold increase in pancreatitis reported in association with these therapies, this translated into an absolute excess risk of only two cases per hundred subjects exposed every three years. The organizations believe that forthcoming data from prospective clinical trials will provide definitive evidence regarding the safety of GLP-1-based therapies. Learn more.
Published in Brief: